<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905839</url>
  </required_header>
  <id_info>
    <org_study_id>130167</org_study_id>
    <secondary_id>13-N-0167</secondary_id>
    <nct_id>NCT01905839</nct_id>
  </id_info>
  <brief_title>A Study of Movement Disorders Using the QMAT At-Home Testing Device</brief_title>
  <official_title>A Longitudinal Study Assessing the Pathophysiology of Movement Disorders Utilizing the QMAT at Home Testing Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Parkinson s disease (PD) affects half a million Americans, causing slow movements, tremors,&#xD;
      stiffness, and trouble walking. Currently, these symptoms are measured by physical exam, but&#xD;
      this is unreliable and requires an office visit. Researchers want to study a different way to&#xD;
      measure PD symptoms, using a home-testing machine called a QMAT device. It can test how&#xD;
      quickly someone moves doing different tasks. Researchers will study how this testing compares&#xD;
      to physical exam testing and whether the device can detect changes in PD symptoms over time.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To see if a home testing device can be used to evaluate Parkinson s disease symptoms.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Adults at least 18 years old with PD.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will have about 22 clinic visits over 5 years. Each visit will take up to 3&#xD;
           hours. Visits will be scheduled along with visits for another study.&#xD;
&#xD;
        -  At visit 1, participants will learn to use the QMAT device and how to send testing&#xD;
           information to the clinic by computer. The device has a computer screen, some buttons,&#xD;
           and some pegs. Participants will get a device to take home and any accessories.&#xD;
&#xD;
        -  Participants will learn 2 QMAT tests. For one, they will press keys as fast as possible.&#xD;
           For the other, they will move pegs into holes. The tests will take a total of about 20&#xD;
           minutes.&#xD;
&#xD;
        -  Participants will take both tests at home, 2 times on the same day each week, once&#xD;
           before their medication, once after.&#xD;
&#xD;
        -  A study coordinator will monitor the participant s computer data and discuss the at-home&#xD;
           testing at the clinic visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives&#xD;
&#xD;
      The purpose of this protocol is to improve the understanding of the pathophysiology of&#xD;
      movement disorders and to assess movement in Parkinson s disease by performing small&#xD;
      behavioral exercises and objectively measuring movements utilizing the QMAT at home testing&#xD;
      device. These devices will be provided by the Kinetics Foundation. We have developed a series&#xD;
      of motor tasks that can be performed with the QMAT, a home-based computer module, so that&#xD;
      data on patient s movement can be collected frequently and prospectively without obligating&#xD;
      the patient to come to a medical center. The study is designed to be observational in nature.&#xD;
&#xD;
      The QMAT device is being implemented to respond to the interest in objectified tests to&#xD;
      monitor, analyze, and further understand the physiological aspects of Parkinson s disease. We&#xD;
      will conduct:&#xD;
&#xD;
        -  Training to patients to perform tasks on the QMAT device and transmit data at home.&#xD;
&#xD;
        -  Training to investigators who do not have prior experience using the system&#xD;
&#xD;
        -  Testing using the QMAT device that may increase knowledge of a disease process,&#xD;
           responsiveness of treatment or be helpful in patient progress evaluations by analyzing&#xD;
           data collected from the at home tests.&#xD;
&#xD;
      This protocol includes only non-invasive techniques with minimal risk to the participants.&#xD;
      The technique has been piloted as part of the 10-N-0009 protocol, Physiological&#xD;
      Investigations in Movement Disorders.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      We intend to study patients with diagnosis of Parkinson Disease.&#xD;
&#xD;
      We will enroll up to 60 participants in order to obtain 48 patients who complete the study.&#xD;
&#xD;
      Design&#xD;
&#xD;
      We will assign and train study participants to use the QMAT device at home. This is a&#xD;
      portable device with a simple keyboard and pegboard interface, storing data from patient&#xD;
      performance at home. There are 2 tasks that are performed using the device. The pegboard task&#xD;
      involves transferring pegs from holes on one side of the device to the opposite side of the&#xD;
      device. The finger tapping test and the digitography tasks involve having the subject press&#xD;
      keys on the keyboard. At enrollment into this study, a time schedule will be discussed with&#xD;
      the participant regarding the schedule that these at home tests require to be conducted. We&#xD;
      will provide the device, all the components, and a data storage thumb-drive to each&#xD;
      participant.&#xD;
&#xD;
      Outcome measures&#xD;
&#xD;
      i. Bradykinesia (fine motor movements):&#xD;
&#xD;
      The component of the apparatus that will test fine motor control will involve finger pads&#xD;
      that will be tapped in alternating fashion by the patient for 30 seconds.&#xD;
&#xD;
      The primary outcome variable will be mean keystroke velocity (completed alternating&#xD;
      cycles/testing period, expressed as cm/sec. Secondary outcomes will be mean frequency&#xD;
      expressed as Hz, mean strike duration, expressed as m/sec and temporal variation of the&#xD;
      duration of finger strike and frequency (issues of fatigue) expressed as the coefficient of&#xD;
      variation (SD/mean). Variation in velocity will be expressed as the SD.&#xD;
&#xD;
      ii. Complex movements: (Pegboard or plugging device):&#xD;
&#xD;
      The At-Home device also contains plugging tasks. Primary outcome: mean movement velocity&#xD;
      expressed as seconds per plugging cycle. This measure can be analyzed statistically for all&#xD;
      movements to correct for outlier responses and errors. A secondary outcome will also be&#xD;
      defatigation (i.e., the linear change of speed during a testing session, expressed as percent&#xD;
      of the cycle-time. The variance of speed will be provided by the standard deviation. A&#xD;
      regression analysis will allow estimates of the part of the variance that is declared by&#xD;
      linear change over the complete task.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 18, 2013</start_date>
  <completion_date type="Actual">April 15, 2015</completion_date>
  <primary_completion_date type="Actual">April 15, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean speed of keystrokes on a repetitive finger movement</measure>
    <time_frame>5 years follow up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean speed of movement on a peg movement task</measure>
    <time_frame>5 years follow up</time_frame>
  </primary_outcome>
  <enrollment type="Actual">3</enrollment>
  <condition>Movement Disorders</condition>
  <condition>Parkinson's Disease</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
          -  Patients will have a diagnosis of Parkinson Disease&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Ability to comply by the schedule and routine of taking the at home tests with the&#xD;
             QMAT system responsibly&#xD;
&#xD;
          -  ability to perform the QMAT testing&#xD;
&#xD;
          -  current or planned enrollment in 12-N-0137: A Phase 1 Open-label Dose Escalation&#xD;
             Safety Study of Convection-Enhanced Delivery (CED) of Adeno-Associated Virus Encoding&#xD;
             Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects with Advanced&#xD;
             Parkinson s Disease&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Have more than 7 alcoholic drinks a week in the case of a woman or 14 alcoholic drinks&#xD;
             a week in the case of a man.&#xD;
&#xD;
          -  Have had a brain tumor, a stroke, head trauma, epilepsy, or a history of seizures.&#xD;
&#xD;
          -  Have major depression or any major mental disorders (axis I disorders).&#xD;
&#xD;
          -  Have other neurologic disorder than a movement disorder&#xD;
&#xD;
          -  Have had a head injury where there was a loss of consciousness for more than a few&#xD;
             seconds.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Codrin I Lungu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord. 2002 Dec;9(2):103-10.</citation>
    <PMID>12473400</PMID>
  </reference>
  <reference>
    <citation>Bronte-Stewart HM, Ding L, Alexander C, Zhou Y, Moore GP. Quantitative digitography (QDG): a sensitive measure of digital motor control in idiopathic Parkinson's disease. Mov Disord. 2000 Jan;15(1):36-47.</citation>
    <PMID>10634240</PMID>
  </reference>
  <reference>
    <citation>MÃ¼ller T, Benz S. Quantification of the dopaminergic response in Parkinson's disease. Parkinsonism Relat Disord. 2002 Jan;8(3):181-6.</citation>
    <PMID>12039429</PMID>
  </reference>
  <verification_date>April 15, 2015</verification_date>
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>September 22, 2018</last_update_submitted>
  <last_update_submitted_qc>September 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rigidity</keyword>
  <keyword>Assessment</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Physiological Measures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

